{"id":2256,"date":"2023-06-25T17:55:01","date_gmt":"2023-06-25T17:55:01","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/treosulfan\/"},"modified":"2023-06-25T18:03:42","modified_gmt":"2023-06-25T18:03:42","slug":"treosulfan","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/treosulfan\/","title":{"rendered":"Treosulfan"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/kidneydiseaseclinic.net\/renaldrugs\/img\/Treosulfan.JPG\"><\/p>\n<h3>  CLINICAL USE<\/h3>\n<p>Alkylating agent for ovarian cancer<\/p>\n<h3> DOSE IN NORMAL RENAL FUNCTION<\/h3>\n<p>IV: 3\u20138 g\/m   2 every 1\u20133 weeks; doses &gt;3 g\/ m2 should be given as an infusion Doses up to 1.5 g\/m   2 have been given IP Oral: 1 g daily in 4 divided doses for 2\u20134   weeks or 1.5 g daily in 3 divided doses for 1 week Or according to local protocol<\/p>\n<h3>  PHARMACOKINETICS<\/h3>\n<li> Molecular weight &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; : 278.3<\/li>\n<li>  %Protein binding  &nbsp; &nbsp; &nbsp;  &nbsp;  &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; : No data<\/li>\n<li>  %Excreted unchanged in urine &nbsp; &nbsp; : 22\u201330<\/li>\n<li> Volume of distribution (L\/kg) &nbsp; &nbsp; &nbsp; : 44\u201388 litres<\/li>\n<li>half-life \u2013 normal\/ESRD (hrs)&nbsp; &nbsp; &nbsp; : 1.5\u20131.94<br \/>\n<h3>  DOSE IN RENAL IMPAIRMENT<\/h3>\n<h4>GFR (mL\/MIN)<\/h4>\n<\/li>\n<li> 20 to 50  &nbsp; &nbsp; : Use a reduced dose<\/li>\n<li> 10 to 20  &nbsp; &nbsp; : Use a reduced dose<\/li>\n<li> &lt;10 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; : Use a reduced dose<br \/>\n<h3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n<li> CAPD  &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;: Unknown dialysability. Dose as in GFR &lt;10 mL\/min<\/li>\n<li> HD &nbsp;  &nbsp; &nbsp;  &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; : Dialysed. Dose as in GFR &lt;10 mL\/min<\/li>\n<li>HDF\/high flux  &nbsp; : Dialysed. Dose as in GFR &lt;10 mL\/min<\/li>\n<li>CAV\/VVHD  &nbsp; &nbsp; &nbsp;: Unknown dialysability. Dose as in GFR 10 to 20   mL\/min<br \/>\n<h3> IMPORTANT DRUG INTERACTIONS<\/h3>\n<p>Potentially hazardous interactions with other drugs<\/li>\n<li>None known<br \/>\n<h3> ADMINISTRATION<\/h3>\n<h4> Reconstition<\/h4>\n<p>20 or 100 mL water for injection for 1 g and   5 g vials respectively<\/p>\n<h4>  Route<\/h4>\n<p>Oral, IV, IP<\/p>\n<h4>  Rate of Administration<\/h4>\n<p>3 g\/m   2 over 5\u201310 minutes (8 g\/m2 over 30 minutes)<\/p>\n<h4>Comments<\/h4>\n<p>Powder reconstitutes easier if water heated   to 25\u201330\u00b0C<\/p>\n<h4>  OTHER INFORMATION<\/h4>\n<p>Treosulfan is a prodrug of a bifunctional   alkylating agent; high and relatively constant bioavailability. Mean urinary excretion of the parent compound is ~15% over 24 hrs Haemorrhagic cystitis has occurred after   intravesical or intravenous administration .<\/li>\n","protected":false},"excerpt":{"rendered":"<p>CLINICAL USE Alkylating agent for ovarian cancer DOSE IN NORMAL<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-2256","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=2256"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2256\/revisions"}],"predecessor-version":[{"id":2320,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2256\/revisions\/2320"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=2256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=2256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=2256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}